A Selective HDAC 1/2 Inhibitor Modulates Chromatin and Gene Expression in Brain and Alters Mouse Behavior in Two Mood-Related Tests
Psychiatric diseases, including schizophrenia, bipolar disorder and major depression, are projected to lead global disease burden within the next decade. Pharmacotherapy, the primary – albeit often ineffective – treatment method, has remained largely unchanged over the past 50 years, highlighting th...
Main Authors: | Schroeder, Frederick A., Lewis, Michael C., Fass, Daniel M., Wagner, Florence F., Zhang, Yan-Ling, Hennig, Krista M., Gale, Jennifer, Zhao, Wen-Ning, Reis, Surya, Barker, Douglas D., Berry-Scott, Erin, Kim, Sung Won, Clore, Elizabeth L., Hooker, Jacob M., Holson, Edward B., Haggarty, Stephen J., Petryshen, Tracey |
---|---|
Other Authors: | McGovern Institute for Brain Research at MIT |
Format: | Article |
Language: | en_US |
Published: |
Public Library of Science
2013
|
Online Access: | http://hdl.handle.net/1721.1/81234 |
Similar Items
-
Probing the role of HDACs and mechanisms of chromatin-mediated neuroplasticity
by: Haggarty, Stephen J., et al.
Published: (2016) -
Kinetically selective inhibitors of histone deacetylase 2 (HDAC2) as cognition enhancers
by: Wagner, F. F., et al.
Published: (2017) -
Dissecting structure–activity-relationships of crebinostat: Brain penetrant HDAC inhibitors for neuroepigenetic regulation
by: Ghosh, Balaram, et al.
Published: (2018) -
Crebinostat: A novel cognitive enhancer that inhibits histone deacetylase activity and modulates chromatin-mediated neuroplasticity
by: Fass, Daniel M., et al.
Published: (2016) -
A Developmental Switch in Microglial HDAC Function
by: Mathys, Hansruedi, et al.
Published: (2019)